Bacil Pharma plans to raise up to ₹50 crore through a Rights Issue, increasing authorized capital to ₹65 crore. The company has also formed a Rights Issue Committee but faces a governance watch point with two independent directors resigning.
Bacil Pharma Plans ₹50 Crore Rights Issue Amidst Board Changes
Bacil Pharma will raise up to ₹50 crore via a Rights Issue, increasing authorized capital to ₹65 crore.
Reader Takeaway: Capital infusion via rights issue is positive, but director resignations raise governance concerns.
What just happened
Bacil Pharma's Board of Directors has approved a plan to raise up to ₹50 crore through a Rights Issue of equity shares. To support this, the authorized share capital will be increased by ₹45 crore, bringing the total authorized capital to ₹65 crore. This move requires shareholder approval.
The company has appointed Purva Sharegistry (India) Private Limited as the Registrar, Axis Bank Limited (Mumbai) as the Banker, and Acuite Ratings & Research Limited as the Monitoring Agency for the issue.
Why this matters
The capital infusion of ₹50 crore is intended to fuel the company's growth or operational needs. The increase in authorized capital provides the necessary headroom for issuing new shares. However, the resignation of two independent directors, Mr. Dinesh Chander Notiyal and Ms. Avani Savjibhai Godhaniya, simultaneously with this major financial move, raises questions about board stability and corporate governance.
The backstory
Bacil Pharma is a pharmaceutical company. This rights issue and capital increase signal a significant financial event for the company. The resignations, however, introduce a governance factor that investors will scrutinize.
What changes now
A 'Rights Issue Committee' has been formed to manage the capital raise. This committee includes Executive Director & CFO Chaitali Kalpataru Shah as Chairman, and Independent Directors Vivek Mukesh Yadav and Omprakash Pyarelal Sonar as members. The company will now proceed with obtaining shareholder approval and finalizing the terms of the Rights Issue.
Risks to watch
The primary risk highlighted is governance stability. The resignation of two independent directors concurrently with a significant capital raise requires careful monitoring to ensure board independence and adherence to good corporate governance practices are maintained. The terms and pricing of the Rights Issue will also be crucial.
Peer comparison
Information on peer capital raises or board changes is not provided in the filing.
Context metrics (time-bound)
- Capital Raise Target: Up to ₹50 crore via Rights Issue.
- Authorized Capital Increase: ₹45 crore (New total: ₹65 crore).
- Resignations: Two Independent Directors resigned.
What to track next
Investors should watch for the detailed terms of the Rights Issue, including the issue price and ratio, and any further communication from the company regarding the reasons for the independent directors' resignations.